IL17A and chronic obstructive pulmonary disease: The area under the curve (AUC) indicates that lncRNAs ANRIL and NEAT1 can distinguish stable COPD patients from AECOPD patients, as well as predict COPD susceptibility and acute exacerbation risk.[20,21] Moreover, the expression levels of the lncRNAs ANRIL and NEAT1 are both correlated with inflammatory cytokines (tumor necrosis factor α [TNF-α], interlenkin [IL]-1β, and IL-17A) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage in COPD patients,[20,21] suggesting that they are potential biomarkers of COPD progression.